LCZ696 is primarily used in the treatment of heart failure, specifically for patients with reduced ejection fraction. It combines two active components that work synergistically to improve cardiovascular outcomes. The drug helps reduce the risk of hospitalization due to heart failure and decreases the likelihood of cardiovascular death. It is also effective in managing symptoms such as shortness of breath and fatigue, improving overall quality of life for patients. Additionally, LCZ696 is sometimes prescribed for hypertension due to its ability to relax blood vessels and lower blood pressure. Its dual-action mechanism makes it a valuable therapeutic option in cardiology.